Literature DB >> 35802376

Evaluation of Infection-Related Hospitalizations and Drug Prescriptions Among Sepsis Survivors in Germany.

Carolin Fleischmann-Struzek1,2, Bianka Ditscheid3, Josephine Storch3, Norman Rose1,2, Melissa Spoden4, Christiane S Hartog5,6, Antje Freytag3.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35802376      PMCID: PMC9270694          DOI: 10.1001/jamanetworkopen.2022.20945

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


× No keyword cloud information.

Introduction

New or recurrent infections and sepsis are leading causes of rehospitalization after sepsis.[1] Although persistent immunosuppression after sepsis is considered a causative factor, patient-inherent risk factors may also contribute to increased risk of recurrent severe infections.[2] The burden of infection in these patients presepsis is unknown. We analyzed the change in infection-related hospitalizations and outpatient drug prescriptions presepsis vs postsepsis.

Methods

This retrospective cohort study was based on health claims data of AOK, a statutory health insurance provider in Germany, for the years 2011 to 2015. The study was approved by the Jena University Hospital Institutional Review Board; informed consent was waived owing to deidentified patient data. This study followed followed the STROBE reporting guideline. Inpatient sepsis cases were identified by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, German Modification (ICD-10-GM) codes between January 1, 2013, and December 31, 2014, among AOK beneficiaries who were older than 15 years and had no sepsis in the 24 months before index hospitalization. We analyzed hospitalizations and drug prescriptions in the 12 months presepsis and postsepsis among sepsis survivors. Hospitalizations were classified as infection- or sepsis-related according to requisite ICD-10-GM hospital discharge diagnoses.[3] Intensive care unit (ICU) treatment was identified by Operation and Procedure Classification System codes for intensive care complex treatment (8-980, 8-98f, 8-98d, 8-98c). We analyzed total drug prescriptions and prescriptions of anti-infectives according to Anatomic Therapeutical Chemical codes (J01, J02, J04A, J05, A07AA, P01AB). Presepsis and postsepsis outcomes were compared using a 2-sided McNemar χ2 test; statistical significance was set at α = .05. Statistical analyses were conducted using SAS Enterprise Guide, version 7.1 (SAS Institute Inc).

Results

Among 23 million AOK beneficiaries, we identified 159 684 sepsis patients, 116 507 of whom survived hospitalization. The mean (SD) age was 73.0 (13.3) years; 52.1% were men and 47.9% were women. Among the survivors, 32.5% had severe sepsis, 27.7% were treated in an ICU, and 7.4% had no preexisting impairments. In the 12 months postsepsis, 66.8% of survivors were rehospitalized and 45.0% were rehospitalized with infection (67.4% of all rehospitalizations). Among all survivors, 11.9% were rehospitalized for recurrent sepsis, 25.9% of whom were admitted to an ICU; 56.6% of sepsis survivors received anti-infective treatment in an outpatient setting. Although hospitalization rates increased by 3.4% from 63.4% in the 12 months presepsis to 66.8% in the 12 months postsepsis (P < .001), the proportion of patients with infection-related hospitalizations increased by 9.6% (presepsis, 35.4% vs postsepsis, 45.0%; P < .001). The proportion of patients with device-related infections nearly doubled from presepsis to postsepsis (Figure). Total outpatient drug prescriptions decreased (97.5% vs 94.1%; P < .001), but the proportion of patients with at least 1 anti-infective prescription increased by 4.0% (52.6% vs 56.6%; P < .001). The increase in hospitalization and infection-related hospitalization rates was highest in patients without preexisting medical, cognitive, or psychological impairments (hospitalization rate, from 22.5% to 54.6% [a 32.1% increase]; infection-related hospitalization rate, from 6.4% to 31.4% [a 25.0% increase]) (Table). Prescriptions of anti-infectives increased consistently across subgroups and were most prominent in the subgroup of survivors without preexisting impairments (16.7%).
Figure.

Comparison of Presepsis and Postsepsis Source of Infection Among Patients With Infection-Related Hospitalization

Table.

Comparison of Hospitalizations, Infection-Related Hospitalizations, and Drug Prescriptions Among Patients Before and After Sepsis Hospitalization

VariableaPatient group
TotalPatients with ≥1 hospitalizationsPatients with infection-related hospitalizationsPatients with ≥1 drug prescriptionsPatients with anti-infective prescriptions
No.No. (%)P valueNo. (%)P valueNo. (%)P valueNo. (%)P value
Sepsis
Severe
Presepsis37 84023 800 (62.9)<.00113 474 (35.6)<.00136 747 (97.1)<.00119 104 (50.5)<.001
Postsepsis37 84025 409 (67.1)17 757 (46.9)34 472 (91.1)20 074 (53.1)
Nonsevere
Presepsis78 66750 082 (63.7)<.00127 785 (35.3)<.00176 805 (97.6)<.00142 121 (53.5)<.001
Postsepsis78 66752 433 (66.6)34 688 (44.1)75 196 (95.6)45 908 (58.4)
ICU admission
Yes
Presepsis32 23820 305 (63.0)<.00110 970 (34.0)<.00130 980 (96.1)<.00115 354 (47.6)<.001
Postsepsis32 23822 407 (69.5)15 426 (47.8)29 371 (91.1)16 440 (51.0)
No
Presepsis84 26953 577 (63.6)<.00130 289 (35.9)<.00182 572 (98.0)<.00145 871 (54.4)<.001
Postsepsis84 26955 435 (65.8)37 019 (43.9)80 297 (95.3)49 542 (58.8)
Prior impairment
Yes
Presepsis107 88571 943 (66.7)<.00140 710 (37.7)<.001106 943 (99.1)<.00158 247 (54.0)<.001
Postsepsis107 88573 137 (67.8)49 735 (46.1)101 708 (94.3)61 566 (57.1)
No
Presepsis86221939 (22.5)<.001549 (6.4)<.0016609 (76.6)<.0012978 (34.5)<.001
Postsepsis86224705 (54.6)2710 (31.4)7960 (92.3)4416 (51.2)
Age, y
<40
Presepsis26491392 (52.5)<.001703 (26.5)<.0012381 (89.9)<.0011610 (60.8)<.001
Postsepsis26491560 (58.9)903 (34.1)2461 (92.9)1734 (65.4)
40-65
Presepsis25 86015 928 (61.6)<.0018406 (32.5)<.00124 472 (94.6).5814 214 (55.0)<.001
Postsepsis25 86017 703 (68.4)11 272 (43.6)24 445 (94.5)15 133 (58.5)
66-80
Presepsis51 78733 889 (65.4)<.00119 076 (36.8)<.00150 831 (98.2)<.00127 158 (52.4)<.001
Postsepsis51 78735 774 (69.1)24 382 (47.1)48 726 (94.1)29 540 (57.0)
>80
Presepsis36 21122 673 (62.6).2913 074 (36.1)<.00135 868 (99.0)<.00118 243 (50.4)<.001
Postsepsis36 21122 805 (63.0)15 888 (43.9)34 036 (94.0)19 575 (54.0)

All presepsis and postsepsis periods are 12 months.

All presepsis and postsepsis periods are 12 months.

Discussion

This study found that infection-related hospitalizations affected 2 of every 3 sepsis survivors in Germany. Although hospitalizations among our study cohort increased by 9.6% postsepsis, more than half of these patients had already contracted infectious diseases requiring hospitalization prior to sepsis. This finding suggests that many sepsis patients are at risk for severe infections presepsis—presumably owing to preexisting immune dysfunction—and that septic insults may exacerbate their risk of developing severe infections and recurrent sepsis.[4] Furthermore, patients without prior impairments and low rates of presepsis infection–related hospitalizations and drug prescriptions had these rates increase substantially postsepsis. This study has some limitations. First, the validity of health claims diagnoses relies on coding quality. Second, subgroup comparisons should be interpreted within the context of differential mortality rates among survivors. Regardless, our findings highlight the need for preventive measures—particularly vaccinations and programs to prevent device-related infections—as well as early recognition and education regarding symptoms among all sepsis survivors and at-risk patients in the general population.
  4 in total

1.  Readmission diagnoses after hospitalization for severe sepsis and other acute medical conditions.

Authors:  Hallie C Prescott; Kenneth M Langa; Theodore J Iwashyna
Journal:  JAMA       Date:  2015-03-10       Impact factor: 56.272

Review 2.  Enhancing Recovery From Sepsis: A Review.

Authors:  Hallie C Prescott; Derek C Angus
Journal:  JAMA       Date:  2018-01-02       Impact factor: 56.272

3.  Subsequent infections in survivors of sepsis: epidemiology and outcomes.

Authors:  Tisha Wang; Ariss Derhovanessian; Sharon De Cruz; John A Belperio; Jane C Deng; Guy Soo Hoo
Journal:  J Intensive Care Med       Date:  2012-12-26       Impact factor: 3.510

4.  Epidemiology and Costs of Postsepsis Morbidity, Nursing Care Dependency, and Mortality in Germany, 2013 to 2017.

Authors:  Carolin Fleischmann-Struzek; Norman Rose; Antje Freytag; Melissa Spoden; Hallie C Prescott; Anna Schettler; Lisa Wedekind; Bianka Ditscheid; Josephine Storch; Sebastian Born; Peter Schlattmann; Christian Günster; Konrad Reinhart; Christiane S Hartog
Journal:  JAMA Netw Open       Date:  2021-11-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.